LCTX (22) IPSC (18) OCGN (25) CABA (33) ⌘ Pro Terminal →

Fate Therapeutics Inc. (FATE) — RQD Stock Rating Cockpit

$2.08 -4.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.06

Fate Therapeutics Inc. (FATE) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $260.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FATE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FATE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Fate Therapeutics Inc. (NASDAQ: FATE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.08 (-4.15% 1D, market cap $260.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FATE ranks #637 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FATE compare to LCTX and IPSC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), FATE carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LCTX (Lineage Cell Therapeutics Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $260.5M) and IPSC (Century Therapeutics Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -14.1%, cap $264.4M). Among the 5-stock peer group, FATE leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FATE?

▼

Per FATE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434316), Fate Therapeutics Inc. generated $6.6M in revenue (-51.2% YoY), -$136.3M in net income, and -$112.0M in free cash flow against $318.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.06 (-0.94%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FATE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY FATE SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (31% of score)

FRED Regime × Technicals: 50% of 52W Range • RSI-14 at 50.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.13-12.7% Next Q

Q2 (-2Q)

Grade D$1.86+10.8% Next Q

Q3 (-1Q)

Grade E$2.06+1% Next Q

Current

Grade D-$2.08-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FATE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FATE currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.29) and Max Pain ($2.18) forces dealer call-delta covering toward $3.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FATE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FATE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

50.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE50% OF RANGE

L: $1$2.08H: $3

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on FATE

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (35)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (38)

12/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like FATE

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FATE)

✓Walkthrough of FATE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FATE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +15.56%▼ DESCENDING CHANNEL

2026-11-02O $2.17H $2.17L $2.08C $2.08VOL 804.3K

RES: $2.43SUP: $1.63SMA50: $2.29SMA200: $1.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FATE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FATE Butterfly Map → + Track FATE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -51.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FATE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FATE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FATE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FATE)

Health Care Rank #637 of 1016 ⚔️ LCTX vs FATE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FATE vs. LCTX, IPSC, OCGN, CABA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Fate Therapeutics Inc. (FATE) ranks #637 by composite RQD confidence (36/100, grade D-) and #543 by equity capitalization ($260.0M). Within this direct 5-issuer industry benchmark cohort, FATE leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently leads its immediate peer cohort in composite quantitative strength at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FATE ACTIVE Fate Therapeutics Inc.	D-	36/100	—	—	-35.0%	-4.15%	$260.0M	Benchmark Subject
LCTX Lineage Cell Therapeutics Inc.	E	22/100	—	—	-35.0%	-2.91%	$260.5M	/lctx-vs-fate →
IPSC Century Therapeutics Inc.	E	18/100	—	—	-14.1%	+0.69%	$264.4M	/ipsc-vs-fate →
OCGN Ocugen Inc.	E	25/100	—	—	-35.0%	-5.58%	$252.4M	/ocgn-vs-fate →
CABA Cabaletta Bio Inc.	E	33/100	—	—	-35.0%	-4.73%	$268.7M	/caba-vs-fate →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001434316

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fate Therapeutics Inc. (FATE) reported GAAP revenue of $6.6M (-51.2% vs. FY2024 revenue of $13.6M , and -89.5% cumulative change since FY2023) , GAAP net income of -$136.3M, operating cash flow of -$106.1M, and free cash flow of -$112.0M (+9.4% YoY). On the balance sheet, FATE closed FY2025 with $318.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.6M	-$136.3M	-$106.1M	-$112.0M	$318.9M	—
FY2024 (FY)	2024-12-31	$13.6M	-$186.3M	-$122.9M	-$123.6M	$440.7M	—
FY2023 (FY)	2023-12-31	$63.5M	-$160.9M	-$132.3M	-$132.3M	—	—

3. FATE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FATE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does FATE compare to LCTX and IPSC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for FATE?

Where is FATE trading relative to its 50-day, 200-day, and 52-week technical levels?

FATE last traded at $2.08 (-4.15% on volume of 1,064,428 shares), positioning the stock -9.17% below its 50-day simple moving average ($2.29) and +6.12% above its 200-day simple moving average ($1.96). Across its 52-week range of $0.95 to $3.23, FATE sits at the 49.6% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.82 to $2.34).

FATE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell FATE stock right now?

Fate Therapeutics Inc. (FATE) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is FATE's 12-month price target and RQD AI Jury consensus?

FATE's 12-month base price target is $1.87 (range $1.46 to $3.39), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: FATE RQD Cockpit FATE 12M Forecast FATE Earnings & Move FATE Dividends & DRIP FATE Insiders & 13F FATE Whale Options FATE Profit Sankey FATE News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

FATE — Fate Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:39:47Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, FATE scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 9/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 7/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5).

The weakest pillar is Insider Conviction, and the Cash Engine pillar is also low, which together indicate that the company's operating economics and insider-level signals do not currently offer strong support for the stock. The Forensic Balance Sheet pillar is middling rather than distressed: an Altman Z of 2.5 and a Piotroski F of 3/9 sit in a weak-to-mixed zone. Whale flow at 9/20 shows some institutional interest but not conviction at scale. Macro fit at 11/20 reflects a beta of 1.0, meaning the stock is rated as moving in line with the broader market rather than amplifying it. For a prospective investor, the RQD framing points to meaningful downside risk tied to continued operating losses, with any upside dependent on improvement in cash generation that the source data does not show.

Recent Catalysts & News Wire Analysis

Market wire (Yahoo Finance Singapore, YELLOW): General market action and institutional positioning coverage.
Risk watch (TradingView, RED): Reports a 12-month price target cut to $6.07, implying 215% upside against the $2.17 price.
Market wire (Stock Titan, YELLOW): Reports the commercial leadership hire of Jamie Harrell, described as having helped commercialize therapies that each exceeded $1B in annual U.S. sales.
Market wire (MarketBeat, YELLOW): Reports the shares crossed above the 50-day moving average.
Market wire (GlobeNewswire, YELLOW): Company announcement of Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, leading CAR T-cell commercialization.
Market wire (Simply Wall St, YELLOW): Coverage of the company's cash burn rate.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the company's current debt obligations, given that the source data lists debt as N/A for all periods?
What drove the decline in revenue from $63.5M in FY 2023 to $6.6M in FY 2025, and is there a path to recurring revenue?
What are the P/E, EV/EBITDA, and EPS figures, which the source data does not provide despite net losses?
How long does the reported cash of $46.6M fund the operating cash burn implied by FY 2025 free cash flow of $-112.0M?
What specific CAR T-cell programs are being commercialized, and what are their timelines?

FATE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Fate Therapeutics Inc. (FATE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FATE Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 7h ago

Fate Therapeutics, Inc. (FATE) stock price, news, quote and history

Yahoo Finance Singapore report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TradingView • 10h ago

Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside

TradingView report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 13h ago

Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics.

Stock Titan report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 16h ago

Fate Therapeutics (NASDAQ:FATE) Shares Cross Above 50-Day Moving Average - Time to Sell?

MarketBeat report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 19h ago

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

GlobeNewswire report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 22h ago

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Simply Wall St report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Fate Therapeutics, Inc. (FATE) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com

Investing.com UK report covering Fate Therapeutics Inc. (FATE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FATE Bull vs. Bear Conversation Board — What's Your Call at $2.08?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FATE 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.91 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is FATE (D- • RQD 36/100) a Buy at $2.17?

Welcome to the FATE (Fate Therapeutics Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.76 (-18.9%)

Spot @ $2.17

Pump the brakes on FATE — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on FATE, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Fate Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.76 (+27.2%)

Spot @ $2.17

FATE cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on FATE, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $2.17 (52-wk range $0.95 - $3.23), any beat on forward guidance forces shorts and underweight funds to chase.